What is the appropriate dosing regimen for mefenamic acid in adults and adolescents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dosing of Mefenamic Acid

For adults and adolescents ≥14 years, mefenamic acid should be dosed at 500 mg initially, followed by 250 mg every 6 hours as needed. 1

Standard Dosing Regimens

Acute Pain Management

  • Initial dose: 500 mg
  • Maintenance: 250 mg every 6 hours
  • Duration: Usually not to exceed one week 1
  • Time to onset: Approximately 30 minutes 2, 3, 4

Primary Dysmenorrhea

  • Initial dose: 500 mg at onset of bleeding or pain
  • Maintenance: 250 mg every 6 hours
  • Duration: Typically 2-3 days (should not be necessary for more than this) 1
  • Clinical trials demonstrate effective treatment when initiated at the start of menses 1

Maximum Daily Dose

The maximum daily dose is 2000 mg (4 × 500 mg) across all indications 2, 3, 4, 5, 6, 4

Important Clinical Considerations

Pediatric Use

Mefenamic acid has not been adequately studied in children <14 years of age 1. The FDA label explicitly states dosing is only established for adolescents ≥14 years and adults. While recent observational data 7 suggests 5 mg/kg three times daily may be used in children ≥6 months, this remains off-label and requires careful consideration given limited safety data 8.

Pharmacokinetic Profile

  • Peak plasma levels: Reached in 2-4 hours 1
  • Half-life: Approximately 2 hours 1
  • Protein binding: >90% bound to albumin 1
  • Metabolism: Via CYP2C9 to active metabolites 1

Duration of Therapy

Mefenamic acid should be used at the lowest effective dose for the shortest duration consistent with treatment goals 1. This is critical because:

  • Prolonged use increases gastrointestinal and renal toxicity risk
  • The drug is designed for short-term symptomatic relief (typically ≤7 days for pain, 2-3 days for dysmenorrhea)

Special Populations Requiring Dose Adjustment

Renal impairment: Mefenamic acid should not be administered to patients with pre-existing renal disease or significantly impaired renal function 1. Both the parent drug and metabolites are primarily renally excreted, creating accumulation risk.

Hepatic impairment: Reduced doses may be necessary as hepatic metabolism is a significant elimination pathway 1. However, specific dosing recommendations are not established—use with extreme caution or avoid.

Elderly patients: While no specific dose reduction is mandated by age alone, increased vigilance is warranted due to age-related decline in renal function and higher risk of adverse effects.

Common Pitfalls to Avoid

  1. Exceeding 2000 mg daily dose: This increases toxicity without additional benefit
  2. Prolonged use beyond one week for pain: Increases GI bleeding, ulceration, and renal toxicity risk
  3. Use in patients with renal disease: Contraindicated due to accumulation risk and nephrotoxicity 1
  4. Combining with other NSAIDs: Increases adverse event risk without improving efficacy
  5. Ignoring GI protection: When used for >3-5 days, consider gastroprotection, particularly in high-risk patients 3

Administration Timing

Mefenamic acid can be taken with or without food, though the FDA label notes that antacids containing magnesium hydroxide significantly increase absorption rate and extent 1. For dysmenorrhea, initiate at the first sign of bleeding or pain for optimal efficacy 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.